AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF PEGAPTANIB OR RANIBIZUMAB IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION
| Autor: | Masahito Ohji, Hajime Kawamura, Taichiro Miyake, Tomoko Sawada, Masashi Kakinoki, Osamu Sawada |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Indocyanine Green
Male Vascular Endothelial Growth Factor A medicine.medical_specialty genetic structures Pegaptanib Visual Acuity Angiogenesis Inhibitors Enzyme-Linked Immunosorbent Assay Antibodies Monoclonal Humanized Injections Aqueous Humor Macular Degeneration chemistry.chemical_compound Ranibizumab Ophthalmology medicine Humans Prospective Studies Fluorescein Angiography Aged Aged 80 and over Detection limit Aqueous solution medicine.diagnostic_test business.industry Antibodies Monoclonal General Medicine Aptamers Nucleotide Middle Aged Macular degeneration medicine.disease Fluorescein angiography Choroidal Neovascularization eye diseases Vitreous Body Vascular endothelial growth factor chemistry Female sense organs business Indocyanine green Tomography Optical Coherence medicine.drug |
| Zdroj: | Retina. 30:1034-1038 |
| ISSN: | 0275-004X |
| DOI: | 10.1097/iae.0b013e3181ce74c8 |
| Popis: | PURPOSE The purpose of this study was to evaluate vascular endothelial growth factor (VEGF) concentrations in the aqueous humor of eyes after intravitreal injections of pegaptanib or ranibizumab in patients with age-related macular degeneration. METHODS Aqueous humor samples were obtained from 16 eyes with choroidal neo-vascularization secondary to age-related macular degeneration before and after intravitreal injections of pegaptanib (0.3 mg; 5 eyes) and ranibizumab (0.5 mg; 11 eyes). The VEGF concentration was measured using an enzyme-linked immunosorbent assay using a primary antibody against VEGF121 and VEGF165. RESULTS The VEGF concentrations in the aqueous humor of eyes with age-related macular degeneration ranged from 35.3 pg/mL to 142.4 pg/mL (mean +/- standard deviation, 90.9 pg/mL +/- 40.0 pg/mL) before the injection of pegaptanib and increased significantly, ranging from 298.2 pg/mL to 571.3 pg/mL (mean +/- standard deviation, 452.0 pg/mL +/- 106.4 pg/mL) 6 weeks after the injection (P = 0.005). The VEGF concentrations ranged from 47.2 pg/mL to 307.4 pg/mL (mean +/- standard deviation, 125.9 pg/mL +/- 77.2 pg/mL) before injection of ranibizumab and decreased to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|